≡ Risteys
R9

Documentation Changelog GitHub Contact & Feedback

Myelofibrosis

DOID EFO MESH PheWeb

MYELOFIBROSIS

primary myelofibrosis: Myelofibrosis with myeloid metaplasia is a myeloproliferative disease with annual incidence of approximately 1 case per 100,000 individuals and age at diagnosis around 60 (an increased prevalence is noted in Ashkenazi Jews). Clinical manifestations depend on the type of blood cell affected and may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension.

Endpoint definition

↥
FinnGen phenotype data

392423 individuals

diagram downward connector

Apply sex-specific rule None

392423

diagram downward connector

Check conditions None

392423

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Hospital Discharge: ICD-10 C94.5
Hospital discharge: ICD-9 2387A
Hospital discharge: ICD-8 209
Cause of death: ICD-10 C94.5
Cause of death: ICD-9 2387A
Cause of death: ICD-8 209

2 out of 7 registries used, show all original rules.

20

diagram downward connector

Check minimum number of events None

20

diagram downward connector

Include endpoints None

20

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

19

diagram downward connector
MYELOFIBROSIS

Control definitions

Control exclude MYELOPROF

Extra metadata

First used in FinnGen datafreeze DF2, additional

Not enough data for upset plot.

Or the full data table

Summary Statistics

↥

Key figures

All Female Male
Number of individuals 19 7 12
Unadjusted prevalence (%) 0.01 0.00 0.01
Mean age at first event (years) 50.57 39.96 56.76

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 - - - -
15 years - - - -
5 years - - - -
1 year - - - -

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: MYELOFIBROSIS – Myelofibrosis
GWS hits:

Survival analyses between endpoints

↥

Not a core endpoint, no data to show.

Drugs most likely to be purchased after Myelofibrosis

↥

Endpoint not on priority list, no data to show.